Business Context and Reporting Period
This Form 8-K filing by Assembly Biosciences, Inc. (ASMB) is dated September 27, 2023. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the notice: the closing bid price of the Common Stock was below $1.00 per share for the last 30 consecutive business days.
Material Changes
The material change reported is the receipt of a delisting notice from Nasdaq due to non-compliance with Listing Rule 5450(a)(1) (minimum bid price requirement). There is no immediate effect on the listing; the stock continues to trade under the symbol "ASMB" on the Nasdaq Global Select Market.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an initial 180-calendar day period, ending March 25, 2024, to regain compliance.
- Compliance Criteria: To meet the standard, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days within the 180-day window.
- Contingency Plan: If compliance is not achieved by March 25, 2024, the company may be eligible for a second 180-day period if it meets other initial listing standards (excluding bid price) and notifies Nasdaq of its intention to cure the deficiency, potentially via a reverse stock split.
- Management Action: Management intends to monitor the stock price and is currently evaluating options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of ASMB stock to assess proximity to the $1.00 threshold.
- Monitor the company's announcements regarding the potential execution of a reverse stock split if the initial compliance period expires without success.
- Review the company's broader financial health in subsequent filings (10-Q/10-K) to understand the underlying causes of the stock price decline.
- Confirm the status of the stock listing on Nasdaq as the March 25, 2024, deadline approaches.